Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
Efficacy of pulsed electromagnetic field therapy on acute radiodermatitis in breast cancer patients: a randomized controlled study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mohamed Mahmoud Hamada, Selim Mohamed N, Mohamed Marwa Elsayed, Elmeligie Mohamed Magdy, Kadry Ahmed Mahmoud, Abdelrazik Reda Kotb, Samir Sara Mohamed, Kamel Roshdy Mohamed, Kamal Kamaleldin Ahmed, Elshazly Mahmoud
Аннотация
PURPOSE: The objective of this research was to synthesize the evidence about the usage of pulsed electromagnetic field (PEMF) in women with breast cancer undergoing hypo-fractionated whole-breast irradiation (HFWBI) for the treatment of acute radiodermatitis.
METHODS: The study included 50 patients (35-55 years) with unilateral breast cancer post-lumpectomy who received HFWBI. They were randomized into Group A (PEMF plus standard skin care) and Group B (standard skin care only). Skin reactions were assessed during PEMF therapy using sonographic skin thickness measurements and RTOG criterion.
RESULTS: After radiation, skin thickness increased in both groups, peaking at 4 weeks (PEMF 2.82 mm; control 2.74 mm, p = 0.030). By 6 weeks, thickness declined in the PEMF group but remained high in controls (p < 0.001), and by 8 weeks PEMF returned near baseline (2.01 mm) while controls stayed thickened (p < 0.001). Skin reactions worsened in both groups by week 4, with more severe cases in controls (36% vs. 12%, p = 0.150). By week 6, PEMF patients mostly had mild reactions (72% Grade 0-1) compared to predominantly severe reactions in controls (84% Grade 2-3, p = 0.001). At 8 weeks, recovery was greater with PEMF, as 52% returned to Grade 0 versus only 8% in controls (p = 0.001).
CONCLUSION: Results such as these indicate that PEMF therapy accelerates recovery from radiotherapy and diminishes the intensity of acute radiodermatitis.
TRIAL REGISTRATION: Trial registration number: NCT06003764. Date of registration: 12 August 2023. Prospectively registered for prospectively registered trials.
METHODS: The study included 50 patients (35-55 years) with unilateral breast cancer post-lumpectomy who received HFWBI. They were randomized into Group A (PEMF plus standard skin care) and Group B (standard skin care only). Skin reactions were assessed during PEMF therapy using sonographic skin thickness measurements and RTOG criterion.
RESULTS: After radiation, skin thickness increased in both groups, peaking at 4 weeks (PEMF 2.82 mm; control 2.74 mm, p = 0.030). By 6 weeks, thickness declined in the PEMF group but remained high in controls (p < 0.001), and by 8 weeks PEMF returned near baseline (2.01 mm) while controls stayed thickened (p < 0.001). Skin reactions worsened in both groups by week 4, with more severe cases in controls (36% vs. 12%, p = 0.150). By week 6, PEMF patients mostly had mild reactions (72% Grade 0-1) compared to predominantly severe reactions in controls (84% Grade 2-3, p = 0.001). At 8 weeks, recovery was greater with PEMF, as 52% returned to Grade 0 versus only 8% in controls (p = 0.001).
CONCLUSION: Results such as these indicate that PEMF therapy accelerates recovery from radiotherapy and diminishes the intensity of acute radiodermatitis.
TRIAL REGISTRATION: Trial registration number: NCT06003764. Date of registration: 12 August 2023. Prospectively registered for prospectively registered trials.